Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051017
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051017
Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography
PUBLISHED:
PAGES: 169 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Duchenne Muscular Dystrophy Treatment Market is estimated to be valued at USD 13,307.8 Mn in 2026 and is expected to reach USD 207,474.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 48.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 13,307.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 48.00% | 2033 Value Projection: | USD 207,474.2 Mn |
Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.
Market Dynamics
Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.
For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).
Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.
Market Segmentation
- Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type (Revenue, USD Mn, 2021 - 2033)
- Molecular-based Therapies
- Steroid Therapy
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Other Therapeutic Approaches and Treatment Types
- Global Duchenne Muscular Dystrophy Treatment Market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals/Clinics
- Ambulatory Centers
- Other End Users
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Pfizer Inc.
- Fibrogen Inc.
- BioMarin
- Sarepta Therapeutics
- Santhera Pharmaceuticals
- PTC Therapeutics
- NS Pharma Inc.
- Nobelpharma Co. Ltd.
- Bristol-Myers Squibb
- Eli Lilly and Company
Product Code: CMI898
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Approach and Treatment Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in prevalence of Duchenne muscular dystrophy
- Lack of standardization and stringent rules/regulations
- Increase in demand for novel drugs or therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Molecular-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Steroid Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Other Therapeutic Approaches and Treatment Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals/Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Other End Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Global Duchenne Muscular Dystrophy Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
7. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fibrogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioMarin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Santhera Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NS Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nobelpharma Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.